Organigram Global (OGI) Cash from Financing Activities (2018 - 2026)
Organigram Global (OGI) posted quarterly Cash from Financing Activities of -$328.9 million for Q1 2026, down 101.16% year-on-year from $28.3 billion in Q1 2025, and down 101816.07% on a QoQ basis from -$322688.8 in Q4 2025.
Organigram Global (OGI) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Organigram Global (OGI) has reported Cash from Financing Activities for 7 consecutive years, with -$328.9 million the latest figure, recorded in Q1 2026.
- Quarterly Cash from Financing Activities fell 101.16% year-over-year to -$328.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.0 billion (up 226.12% YoY) and the FY2025 annual result came in at $28.6 million, down 63.83% from the prior year.
- Cash from Financing Activities slipped to -$328.9 million in Q1 2026 per OGI's latest filing, from -$322688.8 in the prior quarter.
- Over the last five years, Cash from Financing Activities for OGI reached as high as $28.3 billion in Q1 2025 and fell as low as -$328.9 million in Q1 2026.
- A 3-year average of $7.0 billion and a median of -$233645.2 in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2025 — Cash from Financing Activities plunged 123.16% — and 2026, when it sank 101.16%.
- Year by year, Cash from Financing Activities stood at -$144601.5 in 2024, then tumbled by 123.16% to -$322688.8 in 2025, then slumped by 101816.07% to -$328.9 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$328.9 million, -$322688.8, and $28.3 billion for Q1 2026, Q4 2025, and Q1 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Organigram Global | 89.89 Mn | 122.96 Mn | 28.97 Mn | -328.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -328.87 Mn |
| Mar 31, 2026 | -328.87 Mn |
| Dec 31, 2025 | -322,688.83 |
| Dec 31, 2025 | -322,688.83 |
| Mar 31, 2025 | 28.34 Bn |
| Mar 31, 2025 | 28.34 Bn |
| Dec 31, 2024 | -144,601.53 |
| Dec 31, 2024 | -144,601.53 |
| May 31, 2021 | 174.41 Mn |
| May 31, 2021 | 174.41 Mn |
| Feb 28, 2021 | -50.72 Bn |
| Feb 28, 2021 | -50.72 Bn |
| Nov 30, 2020 | 63.19 Bn |
| Nov 30, 2020 | 63.19 Bn |
| Aug 31, 2020 | 34.29 Mn |
| Aug 31, 2020 | 34.29 Mn |
| May 31, 2020 | 19.81 Mn |
| May 31, 2020 | 19.81 Mn |
| Feb 29, 2020 | 52.57 Mn |
| Feb 29, 2020 | 52.57 Mn |